DRUG
MECHANISM
MAIN USE
SIGNATURE TOXICITY
Blocks inactivated Na⁺ channels
Focal, GTC, status (2nd line)
Gingival hyperplasia, hirsutism, nystagmus, ataxia, teratogen, SJS, CYP inducer
Carbamazepine · oxcarbazepine
Na⁺ channel block
Focal seizures, trigeminal neuralgia, bipolar
Agranulocytosis, aplastic anemia, SIADH/hyponatremia, SJS, CYP inducer
Na⁺ channel block, ↓ glutamate release
Focal, GTC, absence, bipolar depression; pregnancy-preferred
SJS/TEN — titrate slowly
Na⁺ block, ↑ GABA, T-type Ca²⁺ block
Broad: GTC, absence, myoclonic; bipolar; migraine
Hepatotoxicity, pancreatitis, NTD, tremor, weight gain, hyperammonemia, CYP inhibitor
Blocks thalamic T-type Ca²⁺ channels
Absence seizures only
GI upset, fatigue, rash, SJS
Binds SV2A synaptic vesicle protein
Focal, GTC, status; few interactions
Irritability, depression, behavior change
α2δ subunit of voltage-gated Ca²⁺ channels
Focal seizures, neuropathic pain, postherpetic neuralgia, fibromyalgia
Sedation, ataxia, edema; renal dosing
Na⁺ block, ↑ GABA, AMPA block, carbonic anhydrase inhibition
Focal, GTC, migraine prophylaxis, weight loss
Kidney stones, cognitive slowing, weight loss, angle-closure glaucoma, metabolic acidosis
Benzodiazepines
lorazepam, diazepam, midazolam
↑ Frequency of GABA-A Cl⁻ channel opening
Status epilepticus, eclampsia (2nd line), alcohol withdrawal seizures
Respiratory depression, sedation
↑ Duration of GABA-A opening
Neonatal seizures, refractory status
Sedation, CYP induction, respiratory depression
Block GABA reuptake · irreversibly inhibit GABA transaminase
Focal seizures · infantile spasms (vigabatrin)
Vigabatrin permanent visual field loss
Felbamate · lacosamide · cannabidiol
NMDA block · slow Na⁺ inactivation · multiple
Refractory epilepsy (Lennox-Gastaut, Dravet)
Felbamate aplastic anemia; lacosamide PR prolongation
NMDA block, Ca²⁺ antagonism
Eclampsia, preeclampsia with severe features
Loss of reflexes → respiratory arrest; antidote calcium gluconate